Market Overview

2 Reasons Seattle Genetics' Clinical Holds Were A Surprise

2 Reasons Seattle Genetics' Clinical Holds Were A Surprise

On Tuesday, Seattle Genetics, Inc. (NASDAQ: SGEN) announced that the FDA had imposed several clinical holds upon the Phase I trials for SGN-CD33A due to cases of hepatic veno-occlusive disease.

Credit Suisse’s Kennen MacKay maintains a Neutral rating on the company, while lowering the price target from $70 to $60.

Surprising Announcement

Expressing surprise at this development, the analyst explained that SGN-CD33A had been designed to address the pitfalls of the antibody-drug conjugate linker technology that had been observed with the drug candidate’s predecessor, Mylotarg.

In addition, MacKay noted that prior to this announcement, there had been no HVOD concerns observed in the early stages of testing for SGN-CD33A.

The analyst also pointed out that “while the incidence of Mylotarg’s HVOD had been commonly attributed to pre-mature cleavage of the cytotoxic payload, concern continues to exist surrounding potential CD33 target-mediated hepatotoxicity.

The PoS estimate in frontline older/unfit AML had been lowered from 70 percent to 30 percent, and from 30 percent to 15 percent for frontline younger/fit AML.

Latest Ratings for SGEN

Feb 2021RBC CapitalMaintainsSector Perform
Feb 2021BarclaysMaintainsEqual-Weight
Feb 2021Piper SandlerMaintainsNeutral

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings


Related Articles (SGEN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target FDA Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

TDOCDA DavidsonMaintains275.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at